I-MAK Co-Founder Discusses How the COVID-19 Pandemic Shed Light on Racial Inequities and Using the Patent System to Reduce Drug Prices
Co-Founder and Executive Director of the Initiative for Medicines, Access & Knowledge (I-MAK) Priti Krishtel shares her thoughts on how [...]
Biogen Controversy Highlights FDA’s Rules Surrounding Expert Panels
The Food and Drug Administration (FDA)’s approval of Biogen’s Aduhelm was based on shaky data. The resulting controversy continues to [...]
Democrats and Republicans Unite in Pushing for Medicare Negotiation Legislation, Could Save $500 Billion
Bipartisan support is building for legislative mechanisms that would lead to reduced healthcare costs in the United States. One key [...]
Payers Must Cover HIV Prevention Drugs Without Cost-Sharing in Two Months
Federal regulations will require payers to cover HIV prevention drugs and care. Gilead’s HIV drug Truvada has faced criticism due [...]
Biogen Unsuccessful in ICER Attack as Aduhelm Controversy Continues
Biogen has attempted to shield itself from the Institute for Clinical and Economic Review (ICER)’s objections to its Alzheimer’s drug, [...]
Voters Seek to Maintain Access to Medication Through Medicare
A recent poll showed that voters strongly support access to prescription drugs through Medicare Part D. In addition, voters are [...]
NICE Upholds Rejection of Expensive Cancer Drug as Calls for Flexible Drug Pricing Models Grow
The National Institute for Health and Care Excellence (NICE) has rejected Zytiga for the second time. Despite evidence that the [...]
New Report Notes 65 Prescription Drug Increases in July 2021, 800 in January
65 drugs have increased in price this month by approximately 3.5%. GoodRx identified drug manufacturers, which include Pfizer, Bristol Myers [...]
Astellas US President Discusses Improving Medication Affordability, Patient-Centered Care, and Learning From COVID-19 Challenges
PhRMA board member and Astellas US President Mark Reisenauer shares his thoughts on improving the healthcare system in the United [...]
Effective Value-Based Healthcare Requires Rejecting Inferior Approaches and Promoting Health Equity
Although many approaches to value-based healthcare have been proposed or implemented in recent years, not all of them adequately address [...]
ICER Proposes Legislative Mechanisms to Keep Prices Low for Drugs Receiving FDA’s Accelerated Approval Designation
The Institute for Clinical and Economic Review (ICER) suggests enacting federal legislation that would keep prices low for drugs receiving [...]
Pelosi Seeks Prescription Drug Pricing Legislation Including Medicare Negotiation as House Report Notes Pharma Spent $577 Billion on Stock Buybacks and Dividends
House Speaker Nancy Pelosi announced she will push for drug pricing legislation to be included in President Biden’s economic budget, [...]
Moderate Democrats Singled Out by Targeted Drug Pricing Ads
Ad campaigns supporting drug pricing reform are being launched in states with moderate Democrats who may vote against healthcare legislation [...]
Pfizer Heart Failure Medication Lawsuit Ruling Could Broadly Impact Medicare, Lead to Expensive Aduhelm Coverage
Pfizer is seeking legal backing for its plan to pay healthcare costs for Medicare patients taking one of its pricy [...]
Cigna Incentive Program Offers $500 to Switch from Biologics to Biosimilars, Drug Savings Could Reach $375 Billion
In an effort to promote biosimilars, Cigna is offering $500 if customers switch to a lower-cost offering. Experts project that [...]
JAMA Article Finds Medicare Overspent on Generics by $2.6 Billion, Costco Delivered Better Value
A recent article published in JAMA Internal Medicine compares Medicare drug spending on generics to Costco. The researchers found that [...]
2021 Managed Healthcare Executive Pharmacy Survey Respondents Consider Impact of Federal Legislation on Drug Prices
The final portion of Managed Healthcare Executive’s 2021 Pharmacy Survey focused on federal legislation as a mechanism to reduce prescription [...]
CEVR Researcher and Author Dan Ollendorf Discusses QALYs, Reducing Prescription Drug Prices Using Value, and HTAs
Dr. Dan Ollendorf of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts University Medical [...]
Will Senate Finance Committee Chair Use Domestic Reference Pricing in Prescription Drug Negotiation Plan?
Allowing Medicare to negotiate prescription drug costs is one method of reducing healthcare costs. Now, Senate Finance Committee Chair Ron [...]
Prescription Drug Prices Increased 3.1% in July 2020 According to GoodRx
GoodRx found that 52 drugs rose in price by 3.1% in July 2020, while no generics upped their prices. Zogenix’s [...]
Vanderbilt and Stanford Professors Discuss 2021 Drug Pricing Reform in JAMA Article, Note Power of Value Assessments and Medicare Negotiation During COVID-19 Pandemic
Dr. Stacie Dusetzina of Vanderbilt University School of Medicine and Dr. Michelle Mello of Stanford Law School and Stanford School [...]
Despite WHO Recommendation, COVID-19 Drug Too Costly and Inaccessible; Will Roche Give Up Monopoly?
The World Health Organization (WHO) has recommended the use of monoclonal antibody tocilizumab in cases of severe COVID-19 illness. However, [...]
2021 Managed Healthcare Executive Pharmacy Survey Results Include Increased Focus on Price Transparency to Reduce Prescription Drug Costs
Managed Healthcare Executive is publishing the results from its recent survey. According to the more than 225 respondents, reducing drug [...]
Interview with University of Washington Professor and Dean Sheds Light on Reimbursing Novel Cell and Gene Therapies
The Evidence Base interviewed the University of Washington’s Sean Sullivan on the intricacies of reimbursement for novel therapies. Although these [...]
Walmart Enters Insulin Industry Amid Criticism
Walmart has announced that it will sell a cheaper version of insulin. Although this move is projected to pass substantial [...]